Described herein are nanoparticle conjugates that demonstrate enhanced penetration of tumor tissue (e.g., brain tumor tissue) and diffusion within the tumor interstitium, e.g., for treatment of cancer. Further described are methods of targeting tumor-associated macrophages, microglia, and/or other cells in a tumor microenvironment using such nanoparticle conjugates. Moreover, diagnostic, therapeutic, and theranostic (diagnostic and therapeutic) platforms featuring such nanoparticle conjugates are described for treating targets in both the tumor and surrounding microenvironment, thereby enhancing efficacy of cancer treatment. Use of the nanoparticle conjugates described herein with other conventional therapies, including chemotherapy, radiotherapy, immunotherapy, and the like, is also envisaged.

In one aspect, a connector assembly includes a delivery conduit defining a conduit lumen and a securable connector configured to secure the delivery conduit to a medical device hub defining a medical device hub lumen. The conduit lumen includes a constant diameter region along a portion of the delivery conduit and a transition region extending from the delivery conduit to the distal end. A transition region diameter of the transition region gradually increases from the constant diameter region to a distal end of the delivery conduit. The securable connector is coupled to an outer surface of the delivery conduit and is slidable along a portion thereof. The securable connector is configured to receive the medical device hub. The securable connector is secured relative to the delivery conduit so as to fluidically couple the conduit lumen with the medical device hub lumen.

Some embodiments relate to imageable radioisotopic microspheres. In some embodiments, the imageable microspheres are radiolabeled with imageable radioisotopes. In some embodiments, the imageable radioisotope is directly coupled to a surface of a substrate of the microsphere. In some embodiments, the imageable microspheres can be used as surrogate particles to predict the distribution of therapeutic microspheres comprising radiotherapeutic isotopes.

Provided herein are therapeutic nanoparticles including a radiolabel, a chelator that is covalently linked to the therapeutic nanoparticle and to the radiolabel, and a nucleic acid molecule that is covalently linked to the therapeutic nanoparticle. The therapeutic nanoparticle has a diameter between about 10 nanometers (nm) to about 30 nm, and the therapeutic nanoparticle is magnetic. Also provided are pharmaceutical compositions containing these therapeutic nanoparticles. Also provided herein are methods of decreasing cancer cell invasion or metastasis in a subject having a cancer and methods of treating a metastatic cancer in a lymph node in a subject that require the administration of these therapeutic nanoparticles to a subject. Also provided herein are methods of detecting, diagnosing, and/or monitoring a metastatic cancer tissue in a subject. Also provided herein are methods of preparing these therapeutic nanoparticles.

Multiphase microspheres for radioembolization include two-phase microspheres and three-phase microspheres prepared by a microfluidic process. The multiphase microspheres include a primary phase and a first secondary phase surrounded by the primary phase. The primary phase includes a first resin. The first secondary phase includes a second resin and at least one of a radioactive isotope or a compound including at least one radioactive element. Three-phase microspheres additionally include a second secondary phase discrete from the first secondary phase and also surrounded by the primary phase. The second secondary phase may be a gas such as air. The microspheres may be formed by a microfluidic process.

Present invention relates to a novel composition administering pharma agents using a bi-phasic recruiting moiety.

Methods and systems for selection of dosimetry levels and sphere amounts of radioactive compounds for use in a radioembolization procedure for procedure planning may include inputting activity parameter information into a dosimetry portal of a dosimetry selection tool; determining a customized activity based on the activity parameter information and one or more customized activity algorithms; generating one or more sphere amount and dosage recommendations based on the customized activity and one or more dosimetry selection algorithms; selecting one of the one or more sphere amount and dosage recommendations as a selected sphere amount and dosage recommendation; and generating a radioactive compound order for the radioembolization procedure based on the customized activity and the selected sphere amount and dosage recommendation.

Described herein are systems and methods for particle-based photodynamic therapy (PDT) for the treatment of diseases such as cancer of the oral cavity and/or ovarian cancer metastases along the lining of the pelvis. The technology includes an imaging system (e.g., a multichannel imaging camera) configured to perform diagnostic and/or therapeutic treatment on diseased tissue. In certain embodiments, the imaging system comprises one or more excitation sources (e.g., one or more lasers) to assess and/or treat diseased tissue.

Disclosed are compositions and methods for identifying a solid tumor cell target. Compositions and methods for treating prostate cancer are also disclosed. Further, cancer therapeutic compositions comprising CT20p are disclosed. Nanoparticles that are conjugated with a targeting ligand that is a substrate for a solid tumor-specific cell protein are disclosed.

Provided is a lung disease drug delivery carrier, in which the carrier includes a disc particle made of polylactide-co-glycolide (PLGA), the disc particle contains therein a drug, the carrier delivers and/or releases the drug therein into a lung, and the disc particle has a size of 1 μm to 5 μm.